Syros Pharmaceuticals Inc Quick Ratio (SYRS) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Syros Pharmaceuticals Inc   (NASDAQ: SYRS)

Syros Pharmaceuticals Inc 's Quick Ratio

SYRS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 2.05 a new company low.

Within Major Pharmaceutical Preparations industry 296 other companies have achieved higher Quick Ratio than Syros Pharmaceuticals Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 768 to 1175.

Explain Quick Ratio?
How much Cash & cash equivalents SYRS´s has?
What are SYRS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SYRS Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change -0.01 % -13.58 % 58.39 % 19.18 % -26.1 %
Y / Y Cash & cash equivalent Change -48.07 % -45.16 % -34.68 % -31.03 % -54.1 %
Quick Ratio MRQ 2.05 3.22 2.9 3.8 3.95
SYRS's Total Ranking # 1175 # 768 # 909 # 737 # 658
Seq. Current Liabilities Change 15.79 % -34.27 % 1.7 % 29.19 % 0.07 %
Seq. Cash & cash equivalent Change -26.2 % -27.09 % -22.38 % 24.33 % -22.06 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 297
Healthcare Sector # 527
Overall Market # 1175


Quick Ratio Statistics
High Average Low
61.92 10.1 2.05
(Jun 30 2017)   (Sep 30 2024)




Financial Statements
Syros Pharmaceuticals Inc 's Current Liabilities $ 28 Millions Visit SYRS's Balance sheet
Syros Pharmaceuticals Inc 's Cash & cash equivalent $ 58 Millions Visit SYRS's Balance sheet
Source of SYRS's Sales Visit SYRS's Sales by Geography


Cumulative Syros Pharmaceuticals Inc 's Quick Ratio

SYRS's Quick Ratio for the trailling 12 Months

SYRS Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 14.22 % 4.76 % -0.7 % -13.79 % -18.58 %
Y / Y Cash & cash equivalent TTM Growth -38.32 % -41.97 % -27.88 % -12.72 % 9.26 %
Quick Ratio TTM 3.03 3.46 3.85 4.8 5.62
Total Ranking TTM # 3949 # 3288 # 3254 # 3221 # 3504
Seq. Current Liabilities TTM Growth -0 % -2.95 % 11.75 % 5.31 % -8.28 %
Seq. Cash & cash equivalent TTM Growth -12.29 % -12.9 % -10.24 % -10.06 % -17.48 %

Quick ratio ranking by company, industry and sector >> Back to SYRS Financial Strength Comparisons >> Go to Compare SYRS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SYRS's Current Liabilities to $28.39 millions, cumulative Quick Ratio to 3.03 below the SYRS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 499 other companies have achieved higher Quick Ratio than Syros Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3288 to 3949.

Explain Quick Ratio?
How much Cash & cash equivalents SYRS´s has?
What are SYRS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 500
Healthcare Sector # 1013
Within the Market # 3949


trailing twelve months Quick Ratio Statistics
High Average Low
8.9 5.36 3.03
(Dec 31 2017)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Madrigal Pharmaceuticals Inc   5.64 $ 998.627  Millions$ 176.969  Millions
Vyne Therapeutics Inc   5.60 $ 70.232  Millions$ 12.538  Millions
Tvardi Therapeutics Inc   5.60 $ 37.061  Millions$ 6.622  Millions
Inmed Pharmaceuticals Inc  5.56 $ 5.626  Millions$ 1.012  Millions
Calcimedica Inc   5.45 $ 14.603  Millions$ 2.679  Millions
Bullfrog Ai Holdings Inc   5.44 $ 4.239  Millions$ 0.779  Millions
Renovorx Inc   5.40 $ 9.563  Millions$ 1.772  Millions
Monopar Therapeutics Inc   5.36 $ 6.020  Millions$ 1.123  Millions
Azitra Inc   5.31 $ 7.260  Millions$ 1.368  Millions
Phathom Pharmaceuticals Inc   5.13 $ 334.678  Millions$ 65.288  Millions
Arcus Biosciences Inc   5.07 $ 1,089.000  Millions$ 215.000  Millions
Spruce Biosciences Inc   5.06 $ 60.055  Millions$ 11.858  Millions
Io Biotech Inc   4.99 $ 80.185  Millions$ 16.055  Millions
Igm Biosciences Inc   4.98 $ 218.787  Millions$ 43.964  Millions
Foghorn Therapeutics Inc   4.71 $ 267.397  Millions$ 56.824  Millions
Chemomab Therapeutics Ltd   4.60 $ 14.266  Millions$ 3.103  Millions
Alx Oncology Holdings Inc  4.59 $ 148.574  Millions$ 32.340  Millions
Sol gel Technologies Ltd   4.53 $ 23.926  Millions$ 5.285  Millions
Clearside Biomedical Inc   4.52 $ 23.591  Millions$ 5.220  Millions
Amylyx Pharmaceuticals Inc   4.35 $ 234.395  Millions$ 53.915  Millions
Enanta Pharmaceuticals Inc  4.31 $ 248.186  Millions$ 57.535  Millions
Cryoport inc   4.25 $ 260.860  Millions$ 61.439  Millions
Catalyst Pharmaceuticals Inc   4.20 $ 442.331  Millions$ 105.395  Millions
Addex Therapeutics Ltd  4.17 $ 3.685  Millions$ 0.885  Millions
Cyclerion Therapeutics Inc   4.10 $ 2.872  Millions$ 0.700  Millions
Arvinas Inc   4.07 $ 1,121.600  Millions$ 275.900  Millions
Atrium Therapeutics Inc   4.05 $ 370.187  Millions$ 91.333  Millions
Talphera Inc   4.02 $ 11.117  Millions$ 2.762  Millions
Cypherpunk Technologies Inc   4.00 $ 62.823  Millions$ 15.717  Millions
Whitehawk Therapeutics Inc   3.96 $ 62.619  Millions$ 15.813  Millions

Date modified: 2026-09-26T07:31:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.